CL2022002521A1 - Composiciones y métodos para inhibir la expresión de angptl3 - Google Patents
Composiciones y métodos para inhibir la expresión de angptl3Info
- Publication number
- CL2022002521A1 CL2022002521A1 CL2022002521A CL2022002521A CL2022002521A1 CL 2022002521 A1 CL2022002521 A1 CL 2022002521A1 CL 2022002521 A CL2022002521 A CL 2022002521A CL 2022002521 A CL2022002521 A CL 2022002521A CL 2022002521 A1 CL2022002521 A1 CL 2022002521A1
- Authority
- CL
- Chile
- Prior art keywords
- angptl3
- expression
- inhibit
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 abstract 3
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991335P | 2020-03-18 | 2020-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002521A1 true CL2022002521A1 (es) | 2023-05-19 |
Family
ID=75478225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002521A CL2022002521A1 (es) | 2020-03-18 | 2022-09-15 | Composiciones y métodos para inhibir la expresión de angptl3 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230287425A1 (enExample) |
| EP (1) | EP4121536A1 (enExample) |
| JP (3) | JP7398007B2 (enExample) |
| KR (1) | KR20220156880A (enExample) |
| CN (1) | CN116096889A (enExample) |
| AU (2) | AU2021236674B2 (enExample) |
| BR (1) | BR112022018667A2 (enExample) |
| CA (1) | CA3172117A1 (enExample) |
| CL (1) | CL2022002521A1 (enExample) |
| IL (1) | IL296549A (enExample) |
| MX (1) | MX2022011550A (enExample) |
| TW (2) | TW202530410A (enExample) |
| WO (1) | WO2021188795A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017021053A2 (en) | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| CA3172117A1 (en) * | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
| US20230383294A1 (en) * | 2020-10-16 | 2023-11-30 | Sanofi | Novel rna compositions and methods for inhibiting angptl3 |
| BR112023017737A2 (pt) | 2021-03-04 | 2023-10-03 | Alnylam Pharmaceuticals Inc | Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas |
| WO2023045994A1 (en) * | 2021-09-23 | 2023-03-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) protein |
| WO2023092102A1 (en) * | 2021-11-19 | 2023-05-25 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof |
| EP4453210A1 (en) * | 2021-12-22 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| JP2025512445A (ja) * | 2022-04-15 | 2025-04-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｃａｐ活性を調節するための組成物及び方法 |
| JP7812495B2 (ja) | 2022-11-23 | 2026-02-09 | イーライ リリー アンド カンパニー | ４’－ホスフェート類似体ヌクレオチドホスホラミダイトを合成する方法 |
| EP4622982A1 (en) | 2022-11-23 | 2025-10-01 | Eli Lilly and Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| EP4638744A1 (en) | 2022-12-22 | 2025-10-29 | Eli Lilly and Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| WO2024151772A2 (en) * | 2023-01-11 | 2024-07-18 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of angptl3, pharmaceutical compositions, and uses thereof |
| WO2024175550A1 (en) * | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| CN118599845A (zh) * | 2023-06-27 | 2024-09-06 | 施能康医药科技(苏州)有限公司 | 靶向人血管生成素样蛋白3的核酸及其用途 |
| WO2025096970A2 (en) * | 2023-11-03 | 2025-05-08 | Basecure Therapeutics Llc | Modified oligonucleotides and methods of use thereof |
| TW202539699A (zh) | 2023-12-08 | 2025-10-16 | 美商美國禮來大藥廠 | 含有治療性寡核苷酸之醫藥組合物及使用其之給藥方案 |
| WO2025169133A1 (en) | 2024-02-09 | 2025-08-14 | Astrazeneca Ab | Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| EP1253199A1 (en) | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| CA2839573A1 (en) * | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| PL3087183T3 (pl) * | 2013-12-24 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji białka angiopoetynopodobnego 3 |
| WO2015168589A2 (en) * | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| BR112017021053A2 (en) * | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| MD3448426T2 (ro) * | 2016-04-28 | 2025-09-30 | Regeneron Pharma | Metode de tratament al pacienților cu hipercolesterolemie familială |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| AU2018224387B2 (en) * | 2017-02-22 | 2024-08-08 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| CN112368381A (zh) * | 2018-04-18 | 2021-02-12 | 迪克纳制药公司 | 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 |
| CA3172117A1 (en) * | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
-
2021
- 2021-03-18 CA CA3172117A patent/CA3172117A1/en active Pending
- 2021-03-18 KR KR1020227036162A patent/KR20220156880A/ko active Pending
- 2021-03-18 TW TW113148812A patent/TW202530410A/zh unknown
- 2021-03-18 WO PCT/US2021/022967 patent/WO2021188795A1/en not_active Ceased
- 2021-03-18 CN CN202180036489.6A patent/CN116096889A/zh active Pending
- 2021-03-18 BR BR112022018667A patent/BR112022018667A2/pt unknown
- 2021-03-18 JP JP2022556016A patent/JP7398007B2/ja active Active
- 2021-03-18 US US17/906,532 patent/US20230287425A1/en active Pending
- 2021-03-18 MX MX2022011550A patent/MX2022011550A/es unknown
- 2021-03-18 AU AU2021236674A patent/AU2021236674B2/en active Active
- 2021-03-18 TW TW110109858A patent/TWI870563B/zh active
- 2021-03-18 IL IL296549A patent/IL296549A/en unknown
- 2021-03-18 EP EP21718336.7A patent/EP4121536A1/en active Pending
-
2022
- 2022-09-15 CL CL2022002521A patent/CL2022002521A1/es unknown
-
2023
- 2023-12-01 JP JP2023203827A patent/JP7749645B2/ja active Active
-
2025
- 2025-05-22 AU AU2025203784A patent/AU2025203784A1/en active Pending
- 2025-09-24 JP JP2025157843A patent/JP2026016378A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220156880A (ko) | 2022-11-28 |
| TWI870563B (zh) | 2025-01-21 |
| MX2022011550A (es) | 2023-01-04 |
| IL296549A (en) | 2022-11-01 |
| JP2023518409A (ja) | 2023-05-01 |
| JP2024041748A (ja) | 2024-03-27 |
| TW202530410A (zh) | 2025-08-01 |
| WO2021188795A1 (en) | 2021-09-23 |
| US20230287425A1 (en) | 2023-09-14 |
| JP7749645B2 (ja) | 2025-10-06 |
| AU2021236674A1 (en) | 2022-10-13 |
| TW202200163A (zh) | 2022-01-01 |
| CA3172117A1 (en) | 2021-09-23 |
| AU2021236674B2 (en) | 2025-03-06 |
| BR112022018667A2 (pt) | 2022-11-29 |
| JP7398007B2 (ja) | 2023-12-13 |
| EP4121536A1 (en) | 2023-01-25 |
| JP2026016378A (ja) | 2026-02-03 |
| CN116096889A (zh) | 2023-05-09 |
| AU2025203784A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018667A2 (pt) | Composições e métodos para inibir a expressão de ang-ptl3 | |
| BR112023001957A2 (pt) | Composições e métodos para inibir expressão de lpa | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2023002953A (es) | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| MX2019013262A (es) | Composiciones cosmeticas para la salud de la piel y metodos de uso de los mismos. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| BR112023020490A2 (pt) | Composições e métodos para expressão de transgenes oculares | |
| BR112022002683A2 (pt) | Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos | |
| CO2021007402A2 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| MY207469A (en) | Therapeutic compounds | |
| ECSP22086300A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| BR112022010411A2 (pt) | Composições bacterianas projetadas e usos das mesmas | |
| CL2023002698A1 (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos | |
| CO2023016136A2 (es) | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1) | |
| MX2024012944A (es) | Producto inmunogeno que comprende il-4 y/o il-13 para el tratamiento de enfermedades asociadas con la expresion o actividad aberrante de il-4 y/o il 13 | |
| BR112023024465A2 (pt) | Usos de um modulador de somatostatina para o tratamento de doença | |
| BR112018000589A2 (pt) | composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| AR127843A1 (es) | Composiciones y métodos para modular la expresión de apoc3 |